Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up.
Fiche publication
Date publication
mars 2024
Journal
Brachytherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ESCHWEGE Pascal, Pr PEIFFERT Didier, Dr DEMOGEOT Nadine
Tous les auteurs :
Jacques J, Sahki N, Meknaci É, Eschwege P, Peiffert D, Demogeot N
Lien Pubmed
Résumé
Brachytherapy (BT) is a standard treatment for low- and favorable intermediate-risk prostate adenocarcinoma. Few studies have focused on young patients. We therefore evaluated long-term efficacy and toxicity of BT in patients aged ≤ 60 years with low- and favorable intermediate-risk prostate cancer.
Mots clés
Age ≤ 60 years, Biochemical failure, Brachytherapy, Prostate cancer
Référence
Brachytherapy. 2024 03 12;: